NantCell, Inc. clinical trials
Acquired by ImmunityBio, Inc., Mar 9, 2021 · source ↗
The registry lists 13 studies whose lead sponsor is NantCell, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 25, 2025.
Before and after it joined ImmunityBio, Inc.
- First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- 13
- First submitted after NantCell, Inc. became part of ImmunityBio, Inc.
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- NantCell, Inc.13 studies
Something wrong with this grouping? Tell us on the ImmunityBio, Inc. page.
Studies
Recruiting first, then most recently updated. Showing 13 of 13. All ImmunityBio, Inc. studies →
- QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEACompletedNCT01147965Phase 1/2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic CancerCompletedNCT00630552Phase 1/2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung CancerTerminatedNCT00807612Phase 1/2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast CancerCompletedNCT00626106Phase 2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung CancerTerminatedNCT00791154Phase 1/2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid TumorsTerminatedNCT00819169Phase 1/2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing CancerTerminatedNCT03127098Phase 1/2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the PancreasCompletedNCT01231347Phase 3
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-3.006 for Recurrent Medullary Thyroid CancerCompletedNCT01856920Phase 2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine ChordomaCompletedNCT02383498Phase 2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell TumorsCompletedNCT00563680Phase 2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCompletedNCT00974896Phase 1
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.
- QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal CarcinomaCompletedNCT00813605Phase 2
Sponsor listed in the registry: NantCell, Inc. · First submitted before NantCell, Inc. became part of ImmunityBio, Inc.